{"id":40339,"date":"2025-08-29T11:37:44","date_gmt":"2025-08-29T03:37:44","guid":{"rendered":"https:\/\/flcube.com\/?p=40339"},"modified":"2025-08-29T11:37:45","modified_gmt":"2025-08-29T03:37:45","slug":"boehringer-ingelheim-sino-biopharma-secure-conditional-approval-for-zongertinib-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=40339","title":{"rendered":"Boehringer\u202fIngelheim &amp; Sino Biopharma Secure Conditional Approval for Zongertinib in China"},"content":{"rendered":"\n<p>In a joint announcement, Boehringer\u202fIngelheim (BI) and Sino Biopharmaceutical Limited (<a href=\"https:\/\/www.google.com\/finance\/quote\/1177:HKG\">HKG: 1177<\/a>) confirmed that the National Medical Products Administration (NMPA) has granted <strong>conditional approval<\/strong> to zongertinib for the treatment of adult patients with unresectable locally advanced or metastatic non\u2011small cell lung cancer (NSCLC) harboring HER2 (ERBB2) activating mutations who have received at least one prior systemic therapy.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-why-zongertinib-is-a-breakthrough\">Why Zongertinib Is a Breakthrough<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First\u2011in\u2011class<\/strong>: Zongertinib is the world\u2019s first and currently the only orally available HER2 tyrosine\u2011kinase inhibitor (TKI) approved for clinical use.<\/li>\n\n\n\n<li><strong>Robust clinical data<\/strong>: The approval hinges on the <strong>Beamion\u2011LUNG\u202f1<\/strong> phase\u202fIII study, which demonstrated impressive efficacy and a favorable safety profile in a heavily pre\u2011treated population.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-beamion-lung-1-key-findings\">Beamion\u2011LUNG\u202f1 Key Findings<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Result<\/th><\/tr><\/thead><tbody><tr><td><strong>Objective Response Rate (ORR)<\/strong><\/td><td><strong>71\u202f%<\/strong> (including 7\u202f% complete responses)<\/td><\/tr><tr><td><strong>Disease Control Rate (DCR)<\/strong><\/td><td><strong>96\u202f%<\/strong><\/td><\/tr><tr><td><strong>Median Duration of Response (DoR)<\/strong><\/td><td><strong>14.1\u202fmonths<\/strong><\/td><\/tr><tr><td><strong>Median Progression\u2011Free Survival (PFS)<\/strong><\/td><td><strong>12.4\u202fmonths<\/strong><\/td><\/tr><tr><td><strong>Treatment Discontinuation Rate<\/strong><\/td><td><strong>2.9\u202f%<\/strong> (manageable safety)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>These outcomes place zongertinib among the most promising targeted therapies for HER2\u2011mutated NSCLC, offering a durable response with minimal discontinuation.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Expansion<\/strong>: The conditional approval opens the Chinese market to a novel oral HER2\u2011TKI, enhancing treatment options for a subset of NSCLC patients that historically had limited choices.<\/li>\n\n\n\n<li><strong>Collaborative Advantage<\/strong>: The partnership between Boehringer\u202fIngelheim\u2019s global expertise and Sino Biopharma\u2019s strong domestic presence positions the drug for accelerated commercialization and reimbursement pathways.<\/li>\n\n\n\n<li><strong>Future Pipeline<\/strong>: Successful market entry may accelerate development of additional HER2\u2011targeted agents and consolidate the companies\u2019 standing in the oncology arena.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>In a joint announcement, Boehringer\u202fIngelheim (BI) and Sino Biopharmaceutical Limited (HKG: 1177) confirmed that the&#8230;<\/p>\n","protected":false},"author":1,"featured_media":40341,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[390,1852,908,15,313,33],"class_list":["post-40339","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-boehringer-ingelheim","tag-conditional-approvals","tag-hkg-1177","tag-product-approvals","tag-sino-biopharmaceutical","tag-tkis-egfr-vegf-btk-etc"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Boehringer\u202fIngelheim &amp; Sino Biopharma Secure Conditional Approval for Zongertinib in China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China\u2019s NMPA grants conditional approval to zongertinib, the world\u2019s first oral HER2\u2011TKI, after the Beamion\u2011LUNG\u202f1 study shows a 71\u202f% ORR and 12.4\u2011month median PFS in HER2\u2011mutated NSCLC.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=40339\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Boehringer\u202fIngelheim &amp; Sino Biopharma Secure Conditional Approval for Zongertinib in China\" \/>\n<meta property=\"og:description\" content=\"China\u2019s NMPA grants conditional approval to zongertinib, the world\u2019s first oral HER2\u2011TKI, after the Beamion\u2011LUNG\u202f1 study shows a 71\u202f% ORR and 12.4\u2011month median PFS in HER2\u2011mutated NSCLC.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=40339\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-29T03:37:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-29T03:37:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2901.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40339#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40339\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Boehringer\u202fIngelheim &amp; Sino Biopharma Secure Conditional Approval for Zongertinib in China\",\"datePublished\":\"2025-08-29T03:37:44+00:00\",\"dateModified\":\"2025-08-29T03:37:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40339\"},\"wordCount\":265,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40339#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2901.webp\",\"keywords\":[\"Boehringer Ingelheim\",\"Conditional approvals\",\"HKG: 1177\",\"Product approvals\",\"Sino Biopharmaceutical\",\"TKIs (EGFR VEGF BTK etc.)\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40339#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40339\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=40339\",\"name\":\"Boehringer\u202fIngelheim &amp; Sino Biopharma Secure Conditional Approval for Zongertinib in China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40339#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40339#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2901.webp\",\"datePublished\":\"2025-08-29T03:37:44+00:00\",\"dateModified\":\"2025-08-29T03:37:45+00:00\",\"description\":\"China\u2019s NMPA grants conditional approval to zongertinib, the world\u2019s first oral HER2\u2011TKI, after the Beamion\u2011LUNG\u202f1 study shows a 71\u202f% ORR and 12.4\u2011month median PFS in HER2\u2011mutated NSCLC.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40339#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40339\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40339#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2901.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2901.webp\",\"width\":1080,\"height\":608,\"caption\":\"Boehringer\u202fIngelheim & Sino Biopharma Secure Conditional Approval for Zongertinib in China\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40339#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Boehringer\u202fIngelheim &amp; Sino Biopharma Secure Conditional Approval for Zongertinib in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Boehringer\u202fIngelheim &amp; Sino Biopharma Secure Conditional Approval for Zongertinib in China - Insight, China&#039;s Pharmaceutical Industry","description":"China\u2019s NMPA grants conditional approval to zongertinib, the world\u2019s first oral HER2\u2011TKI, after the Beamion\u2011LUNG\u202f1 study shows a 71\u202f% ORR and 12.4\u2011month median PFS in HER2\u2011mutated NSCLC.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=40339","og_locale":"en_US","og_type":"article","og_title":"Boehringer\u202fIngelheim &amp; Sino Biopharma Secure Conditional Approval for Zongertinib in China","og_description":"China\u2019s NMPA grants conditional approval to zongertinib, the world\u2019s first oral HER2\u2011TKI, after the Beamion\u2011LUNG\u202f1 study shows a 71\u202f% ORR and 12.4\u2011month median PFS in HER2\u2011mutated NSCLC.","og_url":"https:\/\/flcube.com\/?p=40339","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-29T03:37:44+00:00","article_modified_time":"2025-08-29T03:37:45+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2901.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=40339#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=40339"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Boehringer\u202fIngelheim &amp; Sino Biopharma Secure Conditional Approval for Zongertinib in China","datePublished":"2025-08-29T03:37:44+00:00","dateModified":"2025-08-29T03:37:45+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=40339"},"wordCount":265,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=40339#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2901.webp","keywords":["Boehringer Ingelheim","Conditional approvals","HKG: 1177","Product approvals","Sino Biopharmaceutical","TKIs (EGFR VEGF BTK etc.)"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=40339#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=40339","url":"https:\/\/flcube.com\/?p=40339","name":"Boehringer\u202fIngelheim &amp; Sino Biopharma Secure Conditional Approval for Zongertinib in China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=40339#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=40339#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2901.webp","datePublished":"2025-08-29T03:37:44+00:00","dateModified":"2025-08-29T03:37:45+00:00","description":"China\u2019s NMPA grants conditional approval to zongertinib, the world\u2019s first oral HER2\u2011TKI, after the Beamion\u2011LUNG\u202f1 study shows a 71\u202f% ORR and 12.4\u2011month median PFS in HER2\u2011mutated NSCLC.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=40339#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=40339"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=40339#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2901.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2901.webp","width":1080,"height":608,"caption":"Boehringer\u202fIngelheim & Sino Biopharma Secure Conditional Approval for Zongertinib in China"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=40339#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Boehringer\u202fIngelheim &amp; Sino Biopharma Secure Conditional Approval for Zongertinib in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2901.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40339","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=40339"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40339\/revisions"}],"predecessor-version":[{"id":40342,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40339\/revisions\/40342"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/40341"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=40339"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=40339"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=40339"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}